Estrogen receptor-β protects against colitis-associated neoplasia in mice

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2553-2561

  Saleiro, Diana ^a,b   Murillo, Genoveva ^a   Benya, Richard V ^c   Bissonnette, Marc ^d   Hart, John ^d   Mehta, Rajendra G ^a  

^a IIT RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

azoxymethane; colon cancer; dextran sodium sulfate; estrogen receptor beta; inflammatory bowel disease

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CAVEOLIN 1; CYCLINE; DEXTRAN SULFATE; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 6; MUCIN 1; MUCIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON CARCINOGENESIS; COLON WEIGHT; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DYSPLASIA; ENTERITIS; ESTROGEN RECEPTOR BETA DEFICIENCY; FEMALE; HORMONE ACTION; INFLAMMATION; MOUSE; NONHUMAN; ORGAN SIZE; PATHOGENESIS; POLYP; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CAVEOLIN 1; CELL DIFFERENTIATION; COLITIS; COLON; COLORECTAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCIN-1; MUCIN-2; NEOPLASMS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867076730     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27578     Document Type: Article

References (39)

1. Mattar MC, Lough D, Pishvaian MJ, Charabaty A,. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011; 4: 53-61.
2. Munkholm P,. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1-5.
3. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-51.
4. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
5. Canavan C, Abrams KR, Mayberry J,. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-104.
6. Danese S, Mantovani A,. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010; 29: 3313-23.
7. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7-17.
8. Terzić J, Grivennikov S, Karin E, Karin M,. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14.
9. Harnish DC, Albert LM, Leathurby Y, et al. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G118-25.
10. Kennelly R, Kavanagh DO, Hogan AM, et al. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008; 9: 385-91.
11. Grodstein F, Newcomb PA, Stampfer MJ,. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. AM J Med 2009; 106: 574-82.
12. Kane SV, Reddy D,. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1193-96.
13. Campbell-Thompson M, Lynch IJ, Bhardwaj B,. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 632-40.
14. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 1251-8.
15. Saleiro D, Murillo G, Lubahn DB, et al. Enhanced induction of mucin-depleted foci in estrogen receptor {beta} knockout mice. Cancer Prev Res (Phila) 2010; 3: 1198-04.
16. Giroux V, Bernatchez G, Carrier JC,. Chemopreventive effect of ERβ- Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog 2011; 50: 359-69.
17. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003; 144: 4241-9.
18. Edvardsson K, Ström A, Jonsson P, et al. Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011; 25: 969-79.
19. Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-73.
20. De Robertis M, Massi E, Poeta ML, et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 2011; 10: 9.
21. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-49.
22. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-68.
23. Suzuki R, Kohno H, Sugie S, et al. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004; 95: 721-7.
24. Matusiak D, Murillo G, Carrol RE, et al. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1α-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 2005; 14: 2370-6.
25. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
26. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
27. Hollingsworth MA, Swanson BJ,. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60.
28. Andrianifahanana M, Moniaux N, Batra SK,. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochem Biophys Acta 2006; 1765: 189-222.
29. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002; 295: 1726-9.
30. Byrd JC, Bresalier RS,. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004; 23: 77-99.
31. Curtis Hewitt S, Couse JF, Korach KS,. Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2000; 2: 345-52.
32. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
33. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 2009; 57: 291-4.
34. Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010; 59: 227-35.
35. Goel GA, Kandiel A, Achkar JP, Lashner B,. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 2011; 106: 719-30.
36. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
37. Looijer-van Langen M, Hotte N, Dieleman LA, et al. Estrogen receptor-β signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2011; 300: G621-6.
38. Xiu-Li W, Wen-Jun C, Hui-Hua D, et al. ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-kappaB activation. Mol Immunol 2009; 46: 2413-8.
39. Roman-Blas JA, Castañeda S, Cutolo M, et al. Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken) 2010; 62: 1588-93.